Endocrinology, Diabetology and Andrology Unit, Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy.
Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.
Front Endocrinol (Lausanne). 2021 Jul 26;12:651438. doi: 10.3389/fendo.2021.651438. eCollection 2021.
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors, their treatment being challenging and requiring a multidisciplinary approach. Though the only curative treatment is surgery, up to 50% of patients are diagnosed with metastatic disease. In the last years, neoadjuvant chemo(radio)therapy has become part of the standard of care in the treatment of different cancer types. However, evidence of its efficacy and safety in NEN patients has not yet been confirmed in the literature. The aim of the present review is to perform an extensive review of the scientific evidence for neoadjuvant therapy in patients with gastroenteropancreatic and thoracic NENs.
神经内分泌肿瘤(NENs)是一组异质性肿瘤,其治疗具有挑战性,需要多学科方法。尽管唯一的治愈方法是手术,但多达 50%的患者被诊断为转移性疾病。在过去几年中,新辅助化疗(放疗)已成为治疗不同癌症类型的标准治疗方法的一部分。然而,其在 NEN 患者中的疗效和安全性的证据尚未在文献中得到证实。本综述的目的是对胃肠胰神经内分泌肿瘤和胸内神经内分泌肿瘤患者的新辅助治疗的科学证据进行广泛的回顾。